Background: Seasonal allergic rhinitis (SAR) caused by intermittent exposure to seasonal pollen causes itching, nasal congestion, and repeated sneezing, with profound effects on quality of life, work productivity, and school performance. Although both the genotype and environmental factors can contribute to the immunologic basis of allergic reactions, the molecular underpinnings associated with the pathogenesis of allergic rhinitis are not entirely clear. Methods: To address these questions, nasal epithelial brushings were collected from 29 patients with SAR and 31 control subjects during and after the pollen season. We then implemented an orbitrap-based, bottom-up, label-free quantitative proteomics approach, followed by multivariate analyses to identify differentially abundant (DA) proteins among the 4 sample groups. Results: We identified a total of 133 DA proteins for which the most significantly overrepresented functional category was
Key words: Seasonal allergic rhinitis, nasal epithelia, proteomics, interferon 1 signaling, biomarkers Allergic rhinitis is a chronic inflammatory disease of the upper airways that significantly reduces the quality of life of more than 500 million persons worldwide. 1 It is characterized by rhinorrhea, nasal itching, obstruction, and sneezing and is often associated with detrimental effects on sleep, work, social life, and the ability to concentrate at school. In patients with seasonal allergic rhinitis (SAR), different allergens (pollen types) stimulate the production of corresponding allergen-specific IgE antibodies. Current diagnostic approaches rely heavily on questionnaires or measurements of IgE antibodies to specific allergens. 2 Several genetic and environmental factors have been proposed to predispose to the pathogenesis of SAR, [3] [4] [5] but a major challenge remains in that it partially shares biological mechanisms with asthma, chronic rhinosinusitis, food allergy, and atopic dermatitis. 1, 2, [6] [7] [8] Thus there is a high need to elucidate which mechanisms are crucial in development of the disease and which are consequential to facilitate diagnosis, selection of treatment, and design of new treatment strategies. Because nasal mucus and nasal epithelium are the first barriers against allergens, nasal lavage fluid [9] [10] [11] [12] [13] and nasal mucosal brushings [14] [15] [16] have been used to investigate the underlying molecular signatures of SAR. By and large, these studies are sparse, and knowledge gaps still exist pertaining to the specific molecular mechanisms leading to disease onset and progression. In part, this can be attributed to the fact that thus far, especially at the level of the proteome, only a single study has assessed more than 1 time point. 12 In this regard we have implemented a proteomic assessment of nasal brushings within and outside the pollen season in patients with SAR and healthy control subjects to unravel the molecular basis of SAR. This is the first study to investigate differences in protein abundance within cells of the nasal mucosa during and after the pollen season between patients with SAR and healthy control subjects, the goal of which is to shed more light on the underlying disease mechanisms and identify biomarker candidates. In the long run, such an approach will facilitate development of optimized diagnostic and treatment strategies for SAR.
METHODS

Subjects and sampling
This study was approved by the ethics committee of Helsinki University Central Hospital (5/13/03/00/3). All participants provided written informed consent. At the first visit during the pollen season, participants completed an SAR symptom screening questionnaire and a 10-cm visual analog scale of nasal and ocular symptoms within 1 week. Also, skin prick tests (SPTs) to seasonal (birch, alder, meadow fescue, timothy, and mugwort) and perennial (cat, dog, and the house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae) allergens and nasal brush samples (FLOQSwab; Copan Diagnostics, Murrieta, Calif) from the middle meatus of nasal cavity without anesthesia were performed. At the second visit after the pollen season, visual analog scales and nasal brush sampling were repeated. Inclusion criteria in the SAR group were a positive SPT response to seasonal allergen combined with relevant moderate-to-severe SAR symptoms according to Allergic Rhinitis and its Impact on Asthma classification 1 during spring and no SAR symptoms or recent contact with allergens to which the subjects were sensitized on SPTs during the fall. The healthy control group had negative SPT responses and no SAR symptoms. Patients with perennial allergic rhinitis symptoms, smoking, antibiotic use during the study period, respiratory tract infections, or fever less than a month before sampling were excluded from the analysis. The study cohort comprised 60 subjects: 29 patients with SAR and 31 nonallergic control subjects. The characteristics of the study subjects are summarized in Table I .
Sample preparation for proteomics
The brush end of a nasal sample applicator was chopped into 1.5-mL tubes containing 900 mL of ice-cold 50 mmol/L ammonium bicarbonate (AMBIC) buffer. The tubes were gently mixed to release cells attached to the brush end of the swab, after which they were taken out with sterile forceps and discarded. All samples were stored at 2808C until required. Once thawed, nasal brushings in AMBIC were concentrated in 10K MWCO reverse spin columns (Amicon Ultra, Merck Millipore, Billerica, Mass). Sample lysis and homogenization were carried out by means of tip-sonicating samples on ice 2 times for 15 seconds with intermittent sonicator tip cooling. The lysates were then solubilized in 0.2% RapiGest SF (Waters, Milford, Mass) in 50 mmol/L AMBIC, pH 7.8. The protein concentration of each sample was determined by using a standard BCA protein assay kit (Thermo Scientific, Waltham, Mass). Ten micrograms of each sample was used (and the rest stored for immunoblot validation) to prepare tryptic peptides for sequencing by means of mass spectrometry (MS) and quantification by means of in-solution digestion of proteins. A detailed description of tryptic peptide preparation for label-free quantification is described in detail in the Methods section in this article's Online Repository at www.jacionline.org.
Liquid chromatography-tandem mass spectrometry
Tryptic peptides were prepared, as described in the Methods section in this article's Online Repository, for 10 control subjects and 10 patients with SAR within and outside the allergy season (40 samples in total). Samples were put in autosampler vials and loaded into a nanoLC (Easy nano1000) coupled to a Q Exactive Benchtop MS (Thermo Scientific). Chromatographic separation of peptides was carried out in commercially packed C18 columns (Acclaim PepMap [Thermo Fisher Scientific] C18, 2 mm, 100 A, 75 mm 3 15 cm). Peptides were loaded onto the column with buffer A (5% acetonitrile and 0.1% formic acid) and eluted with a 180-minute linear gradient from 5% to 30% buffer B (100% acetonitrile and 0.1% formic acid), with a single 30-minute wash run alternating between every sample injection. All 40 samples were run in triplicates, resulting in a total of 120 raw files. Mass spectra were acquired in a data-dependent manner by using a top 10 method with an automatic switch between full MS and MS/MS (MS 2 ) scans. The orbitrap analyzer parameters for the full MS scan were resolution of 70,000, mass range of 400 to 1200 m/z, and AGC target of 1e6 ions, whereas those for MS 2 spectra acquisition were resolution of 17,500, AGC target of 5e4 ions, and an isolation window of 2 m/z. Column chromatographic performance was routinely monitored with intermittent injections of 50 fmol of a commercially available BSA peptide mix (Waters), as well as evaluating periodic double-wash runs for carryover peptides.
Data processing
Proteome identification and quantification from liquid chromatographytandem mass spectrometry (LC-MS/MS) data were carried out with a label-free algorithm 17, 18 implemented in MaxQuant software (version 1.5.0.30). Default parameters were used for peptide and protein identification, and for enzyme specificity, trypsin allowing for N-terminal cleavage to proline was chosen. An MS/MS spectra search was carried out against the UniprotKB human database with 86,725 entries to which 245 commonly observed contaminants and all reverse sequences were added. Because of the stochastic nature of MS 2 sequencing (wherein about 30% of sequenced peptides vary between separate LC-MS/MS runs of the same biological sample), the heterogeneity of human samples, and the technical challenge of identifying low-abundance proteins, we created in silico pools of 10 biological replicates belonging to the same phenotypic class: Allergic-Spring (AS), Control-Spring (CS), Allergic-Fall (AF), and Control-Fall (CF). Each pool consisted of biological replicates corresponding to 1 independent LC-MS/MS injection of each sample, resulting in triplicates of every in silico pool, which were denoted as AS_1, AS_2, AS_3, and so on (see Table E1 in this article's Online Repository at www.jacionline.org for experimental design template).
Next, we implemented the ''match between runs and do not require MS/MS for label-free quantification comparisons'' options integrated in MaxQuant software to enable retention time alignment for transfer of identifications across samples in each pool and to ensure that both match-identified and MS 2 -identified peptides are used for pairwise peptide intensity comparisons. This approach decreases the number of nonzero entries available for quantitation and should still yield reliable quantitative data because MS and not MS 2 intensity values are used for label-free quantification in MaxQuant. 18 For proteomic data obtained on the same LC-MS/MS platform, the false discovery rate (FDR) for the ''match between runs'' algorithm was 0.12% and 0.44% for identification transfer across 3 and 11 cell lines, respectively.
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Thus we can expect a ''match between runs'' FDR of about 5% for these 40 nasal brush samples. We elaborate on the relevance and implications of this in silico pooling approach within the context of our data in the Discussion section in this article's Online Repository.
Data analysis
Differential abundance analysis and hierarchical clustering were carried out with Perseus data analysis software. 20 Label-free quantification data were imported into Perseus (version 1.5.6) from MaxQuant output files. All intensity values were log 2 transformed, and protein identifications classified as only identified by site, reverse, potential contaminant were filtered out from the main data frame. Additionally, only protein identifications with nonzero intensity values in all 3 replicate in silico pools in at least 1 group (be it AS, CS, AF, or CF) were used for differential abundance analysis. By using the imputation function in Perseus, the remaining zero-intensity values were replaced with random numbers from a normal distribution reflective of log 2 intensity values for low-abundance measurements.
Multiple hypothesis testing was performed with a Benjamini-Hochberg FDR of 0.05 to determine which protein groups were differentially abundant (DA) among the 4 groups. Protein groups with a fold change in abundance of around 2-fold or more between selected contrast sets were identified by using a standard t test with an FDR of 0.05 and an artificial within-group variance, 
Western blot validation
For validation of LC-MS/MS quantitation, we chose 1 protein that was significantly different between patients with SAR and control subjects only within the allergy season (interferon-inducible GTP-binding protein [MX1], P20591) and 1 protein that was significantly different between patients and 
RESULTS
Protein concentration
No significant differences in nasal brush protein concentrations were observed in patients and control subjects between seasons or within the same season between patients and control subjects. Mean protein concentrations were 6.5 6 2.0 mg/mL (AS, n 5 29), 7.0 6 2.4 mg/mL (CS, n 5 31), 7.5 6 2.2 mg/mL (AF, n 5 29), and 8.2 6 2.7 mg/mL (CF, n 5 31).
Quantitative proteome differences
A total of 3207 proteins were identified. After filtering out contaminants and proteins without triplicate intensity values in at least 1 group, a total of 2198 unique proteins (see Table E2 in this article's Online Repository at www.jacionline.org), corresponding to 2024 protein groups in the AS group, 2090 in the CS group, 2066 in the AF group, and 2107 in the CF group, were retained for differential abundance analysis. One hundred thirty-three proteins were found to be DA (ANOVA; Benjamini-Hochberg FDR, 0.05) across these 4 groups (see Table E3 in this article's Online Repository at www.jacionline. org). Hierarchical clustering of these DA proteins separates all 4 sample groups, with the technical replicates being closest together (Fig 1) . A 2-sample t test with a fold change cutoff at approximately 2 was used to highlight proteins that characterized the SAR and control proteomes within (spring) and outside (fall) the pollen season. As expected, the highest and lowest numbers of DA proteins were observed in the AS/CS (43 proteins) and AF/CF (10 proteins) contrasts, respectively. Eighteen proteins were found to be DA in the AF/AS contrast. The CF/CS contrast, with 21 DA proteins, had the second largest number of DA proteins. The gene names and Gene names in boldface represent those common to the contrast sets specified in Fig 2. fold changes of all DA proteins in specified contrast sets are listed in Table II . The ratio of upregulated versus downregulated proteins for each contrast set are highlighted by volcano plots in Fig 2, A.
To observe the distribution of DA proteins between seasons and between patients with SAR and control subjects, we used Venn diagrams to compare DA proteins for specified contrast sets (Fig 2, B) . Only 2 proteins (PRTN3 and cystatin 1 [CST1]) were DA between patients with SAR and control subjects, irrespective of the season (ie, the AF/CF and AS/CS contrasts), and 3 others, interferon-inducible protein with tetratricopeptide repeats (IFIT) 1, CST1, and IFIT3, were DA between seasons in both patients with SAR and control subjects (ie, AS/AF and CF/CS). Interestingly, although IFIT1, CST1, and IFIT3 are DA in both the AF/AS and CF/CS contrasts, the abundance dynamics are going in opposite directions (Fig 3) ; that is, in the transition from fall to spring, these proteins are upregulated in patients with SAR but downregulated in control subjects. Eight proteins were common between the 2 contrast sets synonymous to disease onset: AS/AF and AS/CS. These proteins are BPI fold-containing family B member 4 (BPIFB4), CST1, guanylate-binding protein (GBP) 5, IFIT1, IFIT2, IFIT3, MX1, and S100 calcium-binding protein A7 (S100A7).
Across all 4 contrast sets, the most significant DA protein was statherin (STATH), and the biggest fold change was observed for IFIT3. STATH and IFIT3 were upregulated 5-fold (FDR, 8e8) and 10-fold (FDR, 2e5), respectively, in the AS group. On the contrary, abundance levels of STATH and IFIT3 were lowest in the CS group.
Pathway analysis
Functional enrichment analysis of DA proteins from all contrast sets are depicted in Fig 4. With the exception of the AF/CF contrast, type 1 interferon signaling is among the top 3 most significantly enriched functions. Outside the pollen season (AF/CF contrast), the most enriched pathways were glycosaminoglycan binding, the cytoplasmic membrane-bound vesicle lumen, and secretory granules. In the AS/CS and AS/AF contrast sets, the response to type I interferon and type I interferon pathways have the most intense interactions. In line with this, gene clusters corresponding to the top enriched GO biological pathways reveal that MX1, ISG20, IFIT1 to IFIT3, HLA-C, and GBP2 for AS/CS contrast and MX1 and IFIT1 to IFIT3 for AS/AF contrast are major proteins involved in type I interferon and defense response associated pathways (Fig 5) .
Western blot validation
Results of quantitative Western blotting with antibodies to MX1 and PRTN3 on the same MS-quantified samples (10 patients with SAR and 10 control subjects), as well as an additional 40 subjects (19 patients with SAR and 21 control subjects), were consistent with LC-MS/MS data (Fig 6) . , and CST1 were found to be DA between seasons in patients with SAR and control subjects. However, although they are upregulated during the pollen season and downregulated outside the pollen season in patients with SAR, the reverse is true in control subjects.
DISCUSSION
Because the nasal epithelium acts as a barrier to the external environment and serves as a relay between foreign agents and the immune system (reviewed by Lambrecht and Hammad 24 ), it has been routinely sampled to uncover the immunologic basis of allergic respiratory diseases. [25] [26] [27] In this study nasal mucosal cells, which are predominantly (80% to 95%) epithelial, 28, 29 were sampled within and outside the pollen season in a well-defined SAR and control cohort. The total number of 2198 unique proteins quantified in this study represents the most comprehensive nasal brush proteome to date. Analysis of proteome abundance dynamics in the contrast sets provides mechanistic insight that potentially reflects genetic predisposition to sensitization, proteome remodeling that protects against sensitization during the transition from fall to spring, and biomarkers of SAR pathophysiology.
Technical limitations are still the major hurdle with regard to sequencing low-level proteins in highly complex samples. A combination of state-of-the-art instrumentation and computational tools can be harnessed to improve MS-based protein identification. 30 The orbitrap-based, data-dependent, label-free quantitative strategy we used in this study is appealing for its dynamic range of quantitation (in the range of 5-6 orders of magnitude 31 ) and the fact that it is better suited for discovery because no predetermined peptide lists are required, as opposed to other targeted approaches. 32 However, the stochastic precursor selection associated with data-dependent label-free quantification hampers its effectiveness, especially in highly complex and heterogeneous biological samples. 33 Sample pooling is most often carried out before LC-MS/MS quantitation, which, although having the advantage of requiring less instrument time and decreasing biological variance between ''treatments,'' has the limitation of potentially masking some proteins that are detectable in individual samples. 34 In our approach to pool samples after LC-MS/MS detection (in silico), individual sample identity is still conserved without increasing biological variance across independent pools. Therefore in silico pooling combined with protein-specific validation is a quantitatively effective strategy to improve proteome coverage in complex samples in discovery proteomics.
We hypothesized that the proteins differentiating between patients with SAR and healthy volunteers, irrespective of the season, could be reflective of underlying genetic differences between these groups. The 2 proteins in our data set that fall within this category (common between the AF/CF and AS/CS groups) are PRTN3 and CST1. Expression of PRTN3, a serine protease implicated in maintenance of endothelial barrier function, 35, 36 was found to be downregulated in patients with SAR compared with control subjects both within and outside the pollen season. Incidentally, increased epithelial permeability is a key pathophysiologic feature of allergic rhinitis. [37] [38] [39] CST1, the second protein from our data in this category, is a member of the cystatin superfamily of cysteine protease inhibitors, which are thought to play a protective role against cysteine proteases of host or foreign origin. 40 In our data CST1 was upregulated and then downregulated during and outside the pollen season, respectively, in patients with SAR. This is in line with microarray studies in a Japanese SAR cohort, wherein the CST1 gene was found to be upregulated in symptomatic patients with SAR exposed to Japanese cedar pollen. 41 In addition, upregulated CST1 transcripts in nasal and bronchial epithelia were recently patented as one of several IL13-dependent biomarkers that can be used to identify asthmatic patients with a high risk of disease exacerbation. 25, 42 In the same study, by using unsupervised clustering, genes with a positive correlation with IL13 levels (among which CST1 showed the second strongest positive correlation) were found to distinguish asthmatic patients with self-reported rhinitis. 25 The second category of DA proteins are those common to both the AS/AF and CS/CF contrasts but with an antagonistic expression profile in patients with SAR and control subjects. In our data set we identified 3 proteins in this category: IFIT1, IFIT3, and CST1. Given that these proteins are among those undergoing the biggest changes in abundance between seasons in patients with SAR, we can deduce that their antagonistic abundance profile observed in control subjects is likely reflective of a distorted protective mechanism in patients with SAR. These antagonistic abundance dynamics (Fig 3) of the nasal epithelial proteome are in line with what was observed for secreted nasal proteins in patients with SAR versus control subjects within and outside the pollen season. 12 The third category of proteins highlighted in this study are candidate biomarkers for diagnosis of SAR. Ideally, their abundance profiles should be directly related to symptom onset and offset, and therefore these are the DA proteins that are common between the AS/AF and AS/CS contrasts. From these 2 contrast sets, we observed an upregulation of MX1 (3-to 4-fold), BPIFB4 (4 fold), IFIT1 (5-to 6-fold), IFIT2 (6-to 7-fold), IFIT3 (7-to 10-fold), CST1 (5-to 6-fold), and GBP5 (4-to 7-fold) and a downregulation of S100A7 (3-fold) in patients with SAR during the allergy season (Table II) . All 8 of these proteins are involved in immune response and immunomodulatory activities. Specifically, upregulation of CST1, IFIT1, IFIT2, IFIT3, GBP5, and MX1 has been shown to mediate/enhance antiviral defense mechanisms in vitro and in vivo. 40, [43] [44] [45] [46] Because the majority of these candidate SAR biomarkers are involved in protection against viral infection, it is not surprising that on a systemic level, interferon 1 signaling was the most significantly affected endogenous pathway. It seems that as a result of nasal epithelial barrier dysfunction and dysregulated protective mechanisms, an exaggerated antiviral-type inflammatory response is triggered in patients with SAR on seasonal exposure to environmental stimuli. These antiviral immune responses might contribute to symptoms and airway hyperreactivity by causing an influx of inflammatory cells that negatively affect airway physiology. In fact, within the context of inflammatory disease, allergic sensitization, viral infections, or both are recognized risk factors of asthma exacerbations in older children and adults with asthma. [47] [48] [49] Thus in the same way it is plausible that in patients with SAR, a dysfunctional and overactivated antiviral response during allergen exposure leads to abnormal production of interferon-inducible proteins. These in turn result in overproduction of proinflammatory cytokines and chemokines, finally leading to exaggerated inflammatory reactions in the nasal mucosa that contribute to the disease phenotype. It is also possible that allergic sensitization increases the susceptibility to viral infection or vice versa.
In conclusion, nasal epithelia continues to be a minimally invasive and highly informative avenue to study SAR. In this study we have provided the most comprehensive nasal brush proteome to date, which serves as an important data source to explore the molecular signatures and underlying pathologic mechanisms of SAR.
Our study identified season-independent differences in the nasal epithelial proteome (PRTN3 and CST1) between patients with SAR and healthy control subjects reflective of potential molecular mechanisms underlying SAR. We also demonstrated that, when compared with that of patients with SAR, the nasal epithelium of healthy subjects undergoes antagonistic proteome remodeling (IFIT1, IFIT3, and CST1) during onset of the pollen season. Therefore, after additional validation, downregulation of PRTN3 and upregulation of CST1 could be used as biomarkers of SAR outside the allergy season, and upregulation of IFIT1 and IFIT3 could be used to confirm SAR development during the allergy season. Finally, SAR pathophysiology appears to be principally mediated through an exacerbated expression of interferon inducible proteins which leads to the aggravated nasal inflammation. Together, our data indicate that type 1 interferon-regulated proteins can play a prominent role in the pathogenesis of SAR, and further studies exploring their diagnostic or therapeutic potential for SAR are warranted.
